Drug Pipeline
« Back to the pipeline
Tregalizumab (BT-061)
Tregalizumab (BT-061)
Company
Biotest/AbbVie
Therapeutic Approach
Injectables
Indication
Psoriasis
Mechanism
immune suppressant (anti-CD4 antibody; activates regulatory T cells)
Phase
Phase II
Get the latest research news and tips on managing your psoriasis and psoriatic arthritis.